Bayer (FRA:BAYN) PT Set at €100.00 by JPMorgan Chase & Co.
Bayer (FRA:BAYN) has been assigned a €100.00 ($116.28) target price by equities research analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday, November 13th. The brokerage presently has a “buy” rating on the healthcare company’s stock. JPMorgan Chase & Co.’s price target would suggest a potential upside of 57.65% from the company’s previous close.
Several other research analysts have also recently issued reports on BAYN. Independent Research set a €85.00 ($98.84) price objective on Bayer and gave the stock a “neutral” rating in a research report on Wednesday, September 5th. DZ Bank reaffirmed a “buy” rating on shares of Bayer in a research report on Monday, July 16th. Commerzbank set a €111.00 ($129.07) target price on Bayer and gave the company a “buy” rating in a research report on Monday, August 13th. Baader Bank set a €140.00 ($162.79) target price on Bayer and gave the company a “buy” rating in a research report on Wednesday, August 1st. Finally, Barclays set a €110.00 ($127.91) target price on Bayer and gave the company a “buy” rating in a research report on Monday, August 13th. Six analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Bayer currently has a consensus rating of “Buy” and an average target price of €90.80 ($105.58).
BAYN traded up €1.06 ($1.23) on Tuesday, hitting €63.43 ($73.76). 5,377,233 shares of the company were exchanged. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: How to use beta for portfolio diversification
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.